NCT00527865View on ClinicalTrials.gov

Single Dose Escalating Study of DAS181 in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
Influenza
Interventions
DRUG

DAS181

DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.

DRUG

Placebo

Capsules containing 10.5 mg of lactose will be supplied as placebo.

Trial Locations (1)

33025

Comprehensive Phase One, Miramar

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Ansun Biopharma, Inc.

INDUSTRY